Table 3.
Adverse reaction.
| Adverse reaction | All | Grade 3-5 | ||||
|---|---|---|---|---|---|---|
| Fruquintinib group (55), n. (%) | Regorafenib group (50), n. (%) | p-value | Fruquintinib group (55), n. (%) | Regorafenib group (50), n. (%) | p-value | |
| ALL | 43 (78.2%) | 44 (88.0%) | 0.182 | 16 (29.1) | 11 (22.0) | 0.406 |
| Hand–foot skin reaction | 12 (21.8) | 22 (44.0) | 0.015 | 4 (7.3) | 6 (12.0) | 0.623 |
| Hypertension | 19 (34.5) | 10 (20.0) | 0.096 | 14 (25.5) | 5 (10.0) | 0.040 |
| Proteinuria | 10 (18.2) | 4 (8.0) | 0.125 | 3 (5.5) | 0 | 0.140 |
| Thrombocytopenia | 5 (9.1) | 3 (6.0) | 0.820 | 1 (1.8) | 1 (2.0) | 1.000 |
| Liver dysfunction (ALT, AST level elevated) | 8 (14.5) | 15 (30.0) | 0.056 | 0 | 2 (4.0) | 0.224 |
| Bilirubin level elevated | 7 (12.7) | 8 (16.0) | 0.632 | 0 | 0 | NA |
| Fatigue | 5 (9.1) | 6 (12.0) | 0.627 | 0 | 0 | NA |
| Hoarseness | 6 (10.9) | 5 (10.0) | 0.879 | 2 (3.6) | 0 | 0.272 |
| Oral mucositis | 9 (16.4) | 7 (14.0) | 0.736 | 0 | 1 (2.0) | 0.476 |
| Decreased appetite | 4 (7.3) | 5 (10.0) | 0.881 | 1 (1.8) | 0 | 0.524 |
| Digestive tract reaction (Nausea/Vomiting) | 2 (3.6) | 3 (6.0) | 0.913 | 1 (1.8) | 0 | 0.524 |
| Occult blood positive | 5 (9.1) | 6 (12.0) | 0.627 | 1 (1.8) | 0 | 0.524 |
| Nose bleed | 3 (5.5) | 2 (4.0) | 1.000 | 0 | 1 (2.0) | 0.476 |
| Diarrhoea | 4 (7.3) | 6 (12.0) | 0.623 | 0 | 0 | NA |
| Myodynia/Arthrodynia | 6 (10.9) | 1 (2.0) | 0.151 | 0 | 0 | NA |
| Aortic dissection | 1 (1.8) | 0 | 0.524 | 1 (1.8) | 0 | 0.524 |
| Acute kidney injury | 1 (1.8) | 0 | 0.524 | 1 (1.8) | 0 | 0.524 |
NA, no available; The bold values represent P<0.05, and the difference is statistically significant.